Pear Therapeutics, Inc. Class A Common Stock
PEAR
PEAR was delisted on the 18th of April, 2023.
53 hedge funds and large institutions have $20.7M invested in Pear Therapeutics, Inc. Class A Common Stock in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 18 increasing their positions, 12 reducing their positions, and 13 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 12
17% less funds holding
Funds holding: 64 → 53 (-11)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
77% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 13
78% less capital invested
Capital invested by funds: $96.3M → $20.7M (-$75.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SoftBank Group
Tokyo,
Japan
|
+$10.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$644K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$109K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$53.3K |
| 5 |
SG Americas Securities
New York
|
+$53.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Scoggin Management
New York
|
-$586K |
| 2 |
PT
Palantir Technologies
Denver,
Colorado
|
-$271K |
| 3 |
DC
Darrow Company
Needham,
Massachusetts
|
-$183K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$132K |
| 5 |
BlackRock
New York
|
-$88.8K |
PEAR Hedge Fund Activity: Q1 2023 in Review
53 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Class A Common Stock (PEAR) for Q1 2023, worth a combined $20.7M — down 78% from $96.3M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of PEAR and 3 opened new positions — a net loss of 10 holders — while 12 trimmed existing stakes and 18 added.
The largest buyer was SoftBank Group, opening a new position worth an estimated $10.9M. The largest seller was Scoggin Management, exiting entirely with an estimated $586K sold.
- 53 institutional investors held Pear Therapeutics, Inc. Class A Common Stock (PEAR) as of Q1 2023, down from 64 in Q4 2022.
- Funds reported $20.7M of Pear Therapeutics, Inc. Class A Common Stock stock for Q1 2023, down 78% quarter-over-quarter.
- 3 funds opened new Pear Therapeutics, Inc. Class A Common Stock positions in Q1 2023 and 13 closed out, a net change of -10 holders.
- The largest Pear Therapeutics, Inc. Class A Common Stock buyer in Q1 2023 was SoftBank Group, an estimated $10.9M added.
- The largest Pear Therapeutics, Inc. Class A Common Stock seller in Q1 2023 was Scoggin Management, an estimated $586K sold.
Based on aggregated 13F filings for Q1 2023.